INSMED ($INSM) posted quarterly earnings results on Thursday, May 8th. The company reported earnings of -$1.42 per share, missing estimates of -$1.36 by $0.06. The company also reported revenue of $92,820,000, missing estimates of $93,919,488 by $-1,099,488.
You can see Quiver Quantitative's $INSM stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
INSMED Insider Trading Activity
INSMED insiders have traded $INSM stock on the open market 106 times in the past 6 months. Of those trades, 0 have been purchases and 106 have been sales.
Here’s a breakdown of recent trading of $INSM stock by insiders over the last 6 months:
- WILLIAM LEWIS (Chair and CEO) has made 0 purchases and 61 sales selling 332,730 shares for an estimated $25,071,674.
- ORLOV S NICOLE SCHAEFFER (Chief People Strategy Officer) has made 0 purchases and 7 sales selling 123,374 shares for an estimated $9,761,246.
- ROGER ADSETT (Chief Operating Officer) has made 0 purchases and 10 sales selling 99,365 shares for an estimated $7,773,352.
- MARTINA M.D. FLAMMER (Chief Medical Officer) has made 0 purchases and 10 sales selling 83,545 shares for an estimated $6,473,339.
- SARA BONSTEIN (Chief Financial Officer) has made 0 purchases and 8 sales selling 71,033 shares for an estimated $5,626,426.
- MICHAEL ALEXANDER SMITH (Chief Legal Officer) has made 0 purchases and 4 sales selling 24,339 shares for an estimated $1,913,400.
- JOHN DRAYTON WISE (Chief Commercial Officer) has made 0 purchases and 6 sales selling 21,507 shares for an estimated $1,536,782.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
INSMED Hedge Fund Activity
We have seen 239 institutional investors add shares of INSMED stock to their portfolio, and 201 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- DARWIN GLOBAL MANAGEMENT, LTD. added 2,463,261 shares (+23.5%) to their portfolio in Q4 2024, for an estimated $170,063,539
- FMR LLC removed 2,335,269 shares (-32.5%) from their portfolio in Q4 2024, for an estimated $161,226,971
- EVERSEPT PARTNERS, LP removed 1,089,404 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $75,212,452
- VANGUARD GROUP INC added 1,075,796 shares (+6.3%) to their portfolio in Q4 2024, for an estimated $74,272,955
- VESTAL POINT CAPITAL, LP removed 700,000 shares (-43.8%) from their portfolio in Q4 2024, for an estimated $48,328,000
- VOLORIDGE INVESTMENT MANAGEMENT, LLC removed 699,574 shares (-94.7%) from their portfolio in Q4 2024, for an estimated $48,298,588
- HOLOCENE ADVISORS, LP added 687,712 shares (+inf%) to their portfolio in Q4 2024, for an estimated $47,479,636
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
INSMED Analyst Ratings
Wall Street analysts have issued reports on $INSM in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- UBS issued a "Buy" rating on 03/06/2025
To track analyst ratings and price targets for INSMED, check out Quiver Quantitative's $INSM forecast page.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
